BofA called Eli Lilly’s (LLY) Q2 report and FY25 guidance raise “refreshing” when compared to weight loss drug peer Novo Nordisk’s (NVO) “troubled Q2,” adding that Lilly’s report featured “No major surprises.” While admitting after the earnings report and the company additionally reporting headline results from its Phase 3 oral GLP1 orforglipron study in obese patients that Lilly is “not for the faint at heart,” the firm sees today’s 15% decline as “way overdone” and “creating a particular opportunity” as it argues that Lilly indisputably “remains in pole position in obesity.” BofA maintains a Buy rating and $1,000 price target on Lilly shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Wainwright says Viking’s VK2735 holds strong as competitor data raises eyebrows
- Eli Lilly Stock (LLY) Plunges 15% as Weight-Loss Pill Trial Disappoints
- Eli Lilly downgraded, Lyft upgraded: Wall Street’s top analyst calls
- Leerink downgrades Eli Lilly with thesis changed after results for orforglipron
- Eli Lilly downgraded to Market Perform from Outperform at Leerink